

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

LA-N-1

RRID:CVCL_1827

Type: Cell Line

Proper Citation

RRID:CVCL_1827

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1827

Proper Citation: RRID:CVCL_1827

Description: Cell line LA-N-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:856461](#), [PMID:2535691](#), [PMID:7037175](#), [PMID:7838528](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18082704](#), [PMID:18165268](#), [PMID:18724359](#), [PMID:18923523](#), [PMID:18923524](#), [PMID:20164919](#), [PMID:20655465](#), [PMID:22213050](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LA-N-1

Synonyms: LAN-1, LAN1, Lan1

Cross References: BTO:BTO_0003542, CLO:CLO_0007240, CLO:CLO_0051542, EFO:EFO_0005391, ArrayExpress:E-MTAB-783, BioSample:SAMN03472327, BioSample:SAMN03473468, cancercellines:CVCL_1827, Cosmic:801740, Cosmic:920240, Cosmic:947710, Cosmic:1019927, Cosmic:1037343, Cosmic:1099140, Cosmic:1109118, Cosmic:1153781, Cosmic:1153809, Cosmic:1161991, Cosmic:1167411, Cosmic:1526627, Cosmic:2131578, Cosmic:2239461, Cosmic:2301574, Cosmic:2393635, Cosmic:2485946, DSMZ:ACC-655, DSMZCellDive:ACC-655, ECACC:06041201, GEO:GSM313802, GEO:GSM333797, GEO:GSM563355, GEO:GSM692872, GEO:GSM1366408, IARC_TP53:21458, ICLC:HTL98005, Progenetix:CVCL_1827, RCB:RCB0483, TOKU-E:4118, Wikidata:Q54901875

ID: CVCL_1827

Record Creation Time: 20220427T220716+0000

Record Last Update: 20260829T234447+0000

Ratings and Alerts

No rating or validation information has been found for LA-N-1.

Warning: Discontinued: ICLC; HTL98005

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Norouzi M, et al. (2026) DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. Cancer letters, 646, 218383.

Guyot C, et al. (2026) IL4i1 activity generates oncometabolites that rescue neuroblastoma cells from oxidative death. Cell reports, 45(6), 117441.

Dong Y, et al. (2026) KSRP-dependent immunogenic cell death induced by pyridazinone derivative IMB5036 drives antitumor immunity in neuroblastoma. FEBS letters.

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Navin I, et al. (2025) TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer immunology research, 13(10), 1576.

Stokes ME, et al. (2023) Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers. Cell chemical biology.

Ferry GM, et al. (2022) A Simple and Robust Single-Step Method for CAR-V β 1 γ T Cell Expansion and Transduction for Cancer Immunotherapy. Frontiers in immunology, 13, 863155.

Böckelmann LC, et al. (2021) YKL-40 protein expression in human tumor samples and human tumor cell line xenografts: implications for its use in tumor models. Cellular oncology (Dordrecht), 44(5), 1183.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. *International journal of cancer*, 148(5), 1219.

Tee AE, et al. (2020) Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. *International journal of cancer*, 147(7), 1928.

Bellamy J, et al. (2020) Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma. *Frontiers in oncology*, 10, 818.